

# A randomised feasibility study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression

<b>Submission date</b> 04/06/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 23/07/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/05/2024	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-comparing-a-single-radiotherapy-treatment-with-a-course-of-radiotherapy-treatments-for-cancer-pressing-on-the-spinal-cord>

## Contact information

### Type(s)

Scientific

### Contact name

Prof Peter J Hoskin

### Contact details

Marie Curie Research Wing  
Mount Vernon Hospital  
Rickmansworth Road  
Northwood  
Middlesex  
Northwood  
United Kingdom  
HA6 2RN  
+44 (0)1923 844533  
peterhoskin@nhs.net

## Additional identifiers

EudraCT/CTIS number

**IRAS number**

**ClinicalTrials.gov number**

NCT00727584

**Secondary identifying numbers**

BRD/07/010

## **Study information**

**Scientific Title**

A randomised feasibility study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression

**Acronym**

SCORAD feasibility study

**Study objectives**

To examine whether a phase III randomised trial comparing a single fraction of radiotherapy with multi-fraction radiotherapy is acceptable to clinicians and patients.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Cornwall and Plymouth Research Ethics Committee approved before patient recruitment began, ref: 07/H0203/167

**Study design**

Randomized controlled feasibility study

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

**Health condition(s) or problem(s) studied**

Metastatic spinal cord compression

**Interventions**

Radiotherapy (single or multiple fractions):

Arm 1: 20 Gy/5 fractions daily for 5 consecutive days

Arm 2: 8 Gy/1 fraction

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Patient accrual per centre over a 12-month period.

**Secondary outcome measures**

1. Ambulatory status at 1, 4, 8 and 12 weeks from day 1 of treatment compared to baseline
2. Bladder and bowel function at baseline compared to week 1, 4, 8 and 12
3. Acute side effects at week 1 and 4 assessed using Radiation Therapy Oncology Group (RTOG) scales
4. Quality of life at week 1, 4, 8 and 12, measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire
5. Further treatment
6. Overall survival at 3, 6 and 12 months
7. Total number of days spent in hospital
8. Preferred place of care
9. Number of patients who were eligible but not randomised and reasons for non-randomisation

**Overall study start date**

01/03/2008

**Completion date**

31/08/2009

**Eligibility****Key inclusion criteria**

1. Proven diagnosis of spinal cord compression on magnetic resonance imaging (MRI)
2. Histologically or cytologically confirmed malignant disease
3. Life expectancy greater than 1 month
4. Aged 18 years or older
5. Able to give informed consent
6. Willing and able to complete assessment forms

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

100

**Total final enrolment**

686

**Key exclusion criteria**

1. Patients for whom surgery or chemotherapy treatment is more appropriate
2. Patient known to be pregnant

**Date of first enrolment**

01/03/2008

**Date of final enrolment**

31/08/2009

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Mount Vernon Hospital**

Northwood

United Kingdom

HA6 2RN

**Sponsor information****Organisation**

University College London (UCL) (UK)

**Sponsor details**

Medical School Administration

Gower Street

London

England

United Kingdom  
WC1E 6BT

**Sponsor type**

University/education

**Website**

<http://www.ucl.ac.uk/cancertrials/>

**ROR**

<https://ror.org/02jx3x895>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK (CRUK) (UK) (ref: C2422/A7932)

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

Not provided at time of registration

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	03/12/2019	04/01/2021	Yes	No
<a href="#">Plain English results</a>			26/10/2022	No	Yes
<a href="#">Results article</a>	Quality-of-life outcomes	05/05/2024	07/05/2024	Yes	No